Research and Innovation for Global Health Transformation (RIGHT) - Call 3
- For more information about the funding Programme, visit the Global Health Page
- RIGHT Intent to Submit form
- RIGHT Call 3 Stage 1 - Guidance for Applicants
- RIGHT Call 3 Stage 1 - Template Standard Application Form
- RIGHT Call 3 Stage 1 - Finance Guidance
- RIGHT Call 3 Stage 1 - Finance Summary Form
- RIGHT Call 3 - Frequently Asked Questions
- PPDA Guidance for Applicants
- PPDA Template Application Form
- PPDA Finance Summary Form
NIHR Research and Innovation for Global Health Transformation (RIGHT) provides research funding to support cutting-edge interdisciplinary applied health research in key areas in countries eligible for Official Development Assistance (ODA), where a strategic and targeted investment can result in a transformative impact.
NIHR RIGHT Call 3 supports equitable partnerships between researchers in low- and middle-income countries (LMIC) and those in the UK to generate new research knowledge and evidence on interventions to improve outcomes for people affected by multimorbidities in countries eligible for ODA funding.
The aims of RIGHT Call 3 are to:
- deliver applied health research for the direct and primary benefit to the health and wealth of people living in ODA-eligible countries affected by multimorbidities
- ensure that the research funded through this call strengthens capacity for research and knowledge exchange through development of equitable partnerships between researchers in the ODA-eligible countries and the UK
- promote interdisciplinary approaches to working, by specifically encouraging applications necessitating expertise and activities associated with a broad range of health-science disciplines, including but not limited to: clinical, health economics, statistics, qualitative and social sciences.
NIHR is seeking applications for NIHR RIGHT Call 3 that address applied health research in the following areas:
1. Development and evaluation of interventions and strategies for improved management of multimorbidity, including but not limited to:
- interventions to prevent stepwise progression of multimorbidity once one long-term condition or infection has been diagnosed
- interventions to improve treatment, management and care of patients with infections prevalent in LMICs that have a known association with development or exacerbation of non-communicable diseases (NCDs)
- interventions for the treatment and prevention of the development of multimorbidity in children and young adults driven by malnutrition, multiple chronic infections and poverty
- scalable treatment and care approaches that integrate the management of multimorbidity/disease clusters associated with infection(s) and/or NCD(s).
- new treatment packages, or new models of care and community-based interventions.
2. Healthcare systems strengthening in ODA-eligible countries: research into health care system improvements for improved treatments, management and care for those affected by multimorbidity in LMICs, including capacity building in the primary care setting.
Please note: All applicants for RIGHT Call 3 are required to submit a mandatory 'Intent to Submit' form online by 29 November 2019 at 13:00 GMT (UK time) to be considered for this call.
After submitting an Intent to Submit form, applicants should not wait for a response from the NIHR secretariat and should continue to submit their Stage 1 application along with their application for a Proposal and Partnership Development Award (PPDA).
PPDA and RIGHT Call 3 applications must be made via the NIHR Central Commissioning Facility's Research Management System. The deadline for PPDA and RIGHT Call 3 Stage 1 applications is 15 January 2020 at 13:00 GMT (UK time) .
Webinars for RIGHT Call 3 will be held on Tuesday, 22 October 2019 to provide information to applicants on the aims, scope and eligibility of the call. Participants in the webinar will have the opportunity to submit written questions throughout the event.
If you have any queries, you can contact the NIHR RIGHT Global Health team by emailing email@example.com or calling 020 8843 8080.